Policy | December 04, 2025
Promotion of indigenous pharmaceutical manufacturing
PLI scheme for Bulk Drugs has a total budgetary outlay of Rs. 6,940 crore
PLI scheme for Bulk Drugs has a total budgetary outlay of Rs. 6,940 crore
The company will initially supply prototypes to diverse customers to evaluate in purification processes for producing gene therapy drugs with a view to swift commercialization
Regulatory clearance strengthens company’s global footprint and expands access to the Australian animal healthcare market
The approval is expected to support the company’s presence in regulated international markets and further strengthen its position as a reliable pharma manufacturing partner
Transition to a fermentation-based globally integrated CDMO platform
Biologics manufacturing veteran brings over two decades of expertise in biosimilars, GMP operations, and large-scale biopharmaceutical manufacturing
Deployment aims to improve serialization efficiency by 45% and enhance regulatory compliance across global export markets
FY26 revenue rises to Rs. 4,359 crore as India’s leading CDMO strengthens global footprint with EU GMP certifications, UK MHRA approval and Europe supplies
Antiviral injection addressing CMV and HSV infections had US market sales of nearly $15 million in the last 12 months
The certification follows an inspection conducted by the Malta Medicines Authority between January 29, 2026, and February 3, 2026
Subscribe To Our Newsletter & Stay Updated
